Hemal Gada1, Ajay J Kirtane1, Kaijun Wang1, Yang Lei1, Elizabeth Magnuson1, Matthew R Reynolds1, Mathew R Williams1, Susheel Kodali1, Torsten P Vahl1, Suzanne V Arnold1, Martin B Leon1, Vinod Thourani1, Wilson Y Szeto1, David J Cohen2. 1. From the Rutgers - Robert Wood Johnson Medical School, New Brunswick, NJ (H.G.); Columbia University Medical Center/New York Presbyterian Hospital and the Cardiovascular Research Foundation, New York, NY (A.J.K., S.K., T.P.V., M.B.L.); Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine (K.W., Y.L., E.M., S.V.A., D.J.C.); Lahey Hospital & Medical Center, Burlington, MA and Harvard Clinical Research Institute, Boston, MA (M.R.R.); NYU Langone Medical Center, New York, NY (M.R.W.); Emory University School of Medicine, Atlanta, GA (V.T.); and University of Pennsylvania School of Medicine, Philadelphia (W.Y.S.). 2. From the Rutgers - Robert Wood Johnson Medical School, New Brunswick, NJ (H.G.); Columbia University Medical Center/New York Presbyterian Hospital and the Cardiovascular Research Foundation, New York, NY (A.J.K., S.K., T.P.V., M.B.L.); Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine (K.W., Y.L., E.M., S.V.A., D.J.C.); Lahey Hospital & Medical Center, Burlington, MA and Harvard Clinical Research Institute, Boston, MA (M.R.R.); NYU Langone Medical Center, New York, NY (M.R.W.); Emory University School of Medicine, Atlanta, GA (V.T.); and University of Pennsylvania School of Medicine, Philadelphia (W.Y.S.). dcohen@saint-lukes.org.
Abstract
BACKGROUND: In the Placement of AoRTic TraNscathetER Valve (PARTNER) randomized controlled trial (RCT), which represented the first exposure to transapical transcatheter aortic valve replacement (TA-TAVR) for many clinical sites, high-risk patients undergoing TA-TAVR derived similar health-related quality of life (HRQoL) outcomes when compared with surgical aortic valve replacement (SAVR). With increasing experience, it is possible that HRQoL outcomes of TA-TAVR may have improved. METHODS AND RESULTS: We evaluated HRQoL outcomes at 1-, 6-, and 12-month follow-ups among 875 patients undergoing TA-TAVR in the PARTNER nonrandomized continued access (NRCA) registry and compared these outcomes with those of the TA-TAVR and SAVR patients in the PARTNER RCT. HRQoL was assessed with the Kansas City Cardiomyopathy Questionnaire (KCCQ), the Medical Outcomes Study Short-Form 12, and the EuroQoL-5D, with the KCCQ overall summary score serving as the primary end point. The NRCA TA-TAVR and RCT TA-TAVR and SAVR groups were generally similar. The primary outcome, the KCCQ summary score, did not differ between the NRCA TA-TAVR and the RCT TA-TAVR group at any follow-up timepoints, although there were small differences in favor of the NRCA cohort on several KCCQ subscales at 1 month. There were no significant differences in follow-up HRQOL between the NRCA-TAVR and the RCT SAVR cohorts on the KCCQ overall summary scale or any of the disease-specific or generic subscales. CONCLUSIONS: Despite greater experience with TA-TAVR in the NRCA registry, HRQoL outcomes remained similar to those of TA-TAVR in the original RCT cohort and no better than those with SAVR. These findings have important implications for patient selection for TAVR when transfemoral access is not an option. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00530894.
RCT Entities:
BACKGROUND: In the Placement of AoRTic TraNscathetER Valve (PARTNER) randomized controlled trial (RCT), which represented the first exposure to transapical transcatheter aortic valve replacement (TA-TAVR) for many clinical sites, high-risk patients undergoing TA-TAVR derived similar health-related quality of life (HRQoL) outcomes when compared with surgical aortic valve replacement (SAVR). With increasing experience, it is possible that HRQoL outcomes of TA-TAVR may have improved. METHODS AND RESULTS: We evaluated HRQoL outcomes at 1-, 6-, and 12-month follow-ups among 875 patients undergoing TA-TAVR in the PARTNER nonrandomized continued access (NRCA) registry and compared these outcomes with those of the TA-TAVR and SAVR patients in the PARTNER RCT. HRQoL was assessed with the Kansas City Cardiomyopathy Questionnaire (KCCQ), the Medical Outcomes Study Short-Form 12, and the EuroQoL-5D, with the KCCQ overall summary score serving as the primary end point. The NRCA TA-TAVR and RCT TA-TAVR and SAVR groups were generally similar. The primary outcome, the KCCQ summary score, did not differ between the NRCA TA-TAVR and the RCT TA-TAVR group at any follow-up timepoints, although there were small differences in favor of the NRCA cohort on several KCCQ subscales at 1 month. There were no significant differences in follow-up HRQOL between the NRCA-TAVR and the RCT SAVR cohorts on the KCCQ overall summary scale or any of the disease-specific or generic subscales. CONCLUSIONS: Despite greater experience with TA-TAVR in the NRCA registry, HRQoL outcomes remained similar to those of TA-TAVR in the original RCT cohort and no better than those with SAVR. These findings have important implications for patient selection for TAVR when transfemoral access is not an option. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00530894.
Authors: E A Grossi; P K Zakow; G Ribakove; K Kallenbach; P Ursomanno; C E Gradek; F G Baumann; S B Colvin; A C Galloway Journal: Eur J Cardiothorac Surg Date: 1999-11 Impact factor: 4.191
Authors: Giuseppe D'Ancona; Miralem Pasic; Axel Unbehaun; Stephan Dreysse; Thorsten Drews; Semih Buz; Marian Kukucka; Alexander Mladenow; Roland Hetzer; Burkhardt Seifert Journal: Ann Thorac Surg Date: 2013-09-29 Impact factor: 4.330
Authors: Joel A Lardizabal; Brian P O'Neill; Harit V Desai; Conrad J Macon; Alexis P Rodriguez; Claudia A Martinez; Carlos E Alfonso; Martin S Bilsker; Roger G Carillo; Mauricio G Cohen; Alan W Heldman; William W O'Neill; Donald B Williams Journal: J Am Coll Cardiol Date: 2013-04-10 Impact factor: 24.094
Authors: Kathleen W Wyrwich; John A Spertus; Kurt Kroenke; William M Tierney; Ajit N Babu; Fredric D Wolinsky Journal: Am Heart J Date: 2004-04 Impact factor: 4.749
Authors: Todd M Dewey; Bruce Bowers; Vinod H Thourani; Vasilis Babaliaros; Craig R Smith; Martin B Leon; Lars G Svensson; E Murat Tuzcu; D Craig Miller; Paul S Teirstein; Jeffrey Tyner; David L Brown; Gregory P Fontana; Raj R Makkar; Mathew R Williams; Isaac George; Ajay J Kirtane; Joseph E Bavaria; Michael J Mack Journal: Ann Thorac Surg Date: 2013-08-20 Impact factor: 4.330
Authors: Vinod H Thourani; Rebecca L Gunter; Soumya Neravetla; Peter Block; Robert A Guyton; Patrick Kilgo; Stamatios Lerakis; Chandan Devireddy; Bradley Leshnower; Kreton Mavromatis; James Stewart; Amy Simone; Patricia Keegan; Tom C Nguyen; John Merlino; Vasilis Babaliaros Journal: Ann Thorac Surg Date: 2013-08-21 Impact factor: 4.330
Authors: Caroline A Kim; Suraj P Rasania; Jonathan Afilalo; Jeffrey J Popma; Lewis A Lipsitz; Dae Hyun Kim Journal: Ann Intern Med Date: 2014-02-18 Impact factor: 25.391
Authors: Laura Besola; Anson Cheung; Jian Ye; Myriam Akodad; Andrew Chatfield; Gnalini Sathananthan; Robert Moss; John Webb Journal: Ann Cardiothorac Surg Date: 2021-09
Authors: Jayendrakumar S Patel; Amar Krishnaswamy; Lars G Svensson; E Murat Tuzcu; Stephanie Mick; Samir R Kapadia Journal: Curr Cardiol Rep Date: 2016-11 Impact factor: 2.931
Authors: Sameer A Hirji; Fernando Ramirez-Del Val; Ahmed A Kolkailah; Julius I Ejiofor; Siobhan McGurk; Ritam Chowdhury; Jiyae Lee; Pinak B Shah; Piotr S Sobieszczyk; Sary F Aranki; Marc P Pelletier; Prem S Shekar; Tsuyoshi Kaneko Journal: Ann Cardiothorac Surg Date: 2017-09
Authors: Dae Hyun Kim; Jonathan Afilalo; Sandra M Shi; Jeffrey J Popma; Kamal R Khabbaz; Roger J Laham; Francine Grodstein; Kimberly Guibone; Eliah Lux; Lewis A Lipsitz Journal: JAMA Intern Med Date: 2019-03-01 Impact factor: 21.873
Authors: Sandra B Lauck; Maggie Yu; Lillian Ding; Sean Hardiman; Daniel Wong; Janarthanan Sathananthan; Jian Ye; Albert Chan; Steven Hodge; Simon Robinson; David A Wood; John G Webb Journal: CJC Open Date: 2021-04-24
Authors: Maximilian A Fliegner; Devraj Sukul; Michael P Thompson; Nirav J Shah; Reza Soroushmehr; Jeffrey S McCullough; Donald S Likosky Journal: Int J Cardiol Heart Vasc Date: 2021-09-06
Authors: Stephanie Louise Swift; Thomas Puehler; Kate Misso; Shona Helen Lang; Carol Forbes; Jos Kleijnen; Marion Danner; Christian Kuhn; Assad Haneya; Hatim Seoudy; Jochen Cremer; Norbert Frey; Georg Lutter; Robert Wolff; Fueloep Scheibler; Kai Wehkamp; Derk Frank Journal: BMJ Open Date: 2021-12-06 Impact factor: 2.692